Eric Jonasch, MD

Eric Jonasch, MD, discusses the mechanism of action of NKT-2152.

Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.

Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.

Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.

Dr Eric Jonasch factors that contribute to a patient’s risk status, and how a patient’s risk status impacts front-line treatment choices for patients with advanced RCC.

Eric Jonasch, MD, presents the case of a 72-year-old man with advanced renal cell carcinoma, shares his initial impression.

Eric Jonasch, MD, discusses the 3-year follow-up of the LITESPARK-001 trial of belzutifan in patients with clear cell renal cell carcinoma.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).